Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy

J Thorac Oncol. 2019 Jan;14(1):e5-e7. doi: 10.1016/j.jtho.2018.08.2033.

Authors

Laura Bonanno¹, Alberto Pavan², Ilaria Attili², Giulia Pasello³, Valentina Guarneri²

Affiliations

¹ Medical Oncology 2, Veneto Institute of Oncology IOV IRCCS, Padua, Italy. Electronic address: [email protected].
² Medical Oncology 2, Veneto Institute of Oncology IOV IRCCS, Padua, Italy; Department of Surgery, Oncology, and Gastroenterology, Univeristy of Padua, Padua, Italy.
³ Medical Oncology 2, Veneto Institute of Oncology IOV IRCCS, Padua, Italy.

PMID: 30579553
DOI: 10.1016/j.jtho.2018.08.2033

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Humans
Immunotherapy / methods*
Lung Neoplasms / complications*
Lung Neoplasms / radiotherapy*
Male
Neoplasms, Squamous Cell / complications
Neoplasms, Squamous Cell / radiotherapy*
Pneumonia / etiology*